Comparison

LC3 Antibody (APG8C) (C-term) Blocking peptide

Item no. ABC-BP1804b
Manufacturer Abcepta
Amount 500 ug
Category
Type Peptides
Format Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Specific against other
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Similar products MAP1LC3C, Microtubule-associated proteins 1A/1B light chain 3C, Autophagy-related protein LC3 C, Autophagy-related ubiquitin-like modifier LC3 C, MAP1 light chain 3-like protein 3, MAP1A/MAP1B light chain 3 C, Microtubule-associated protein 1 light chain 3 gamma, MAP1A/MAP1B LC3 C
Available
Primary Accession
Q9BXW4
Bio Background
Autophagy is a process of intracellular bulk degradation in which cytoplasmic components including organelles are sequestered within double-membrane vesicles that deliver the contents to the lysosome/vacuole for degradation. There are three primary forms of autophagy: chaperone-mediated autophagy, microautophagy and macroautophagy. During macroautophagy, the sequestering vesicles, termed autophagosomes, fuse with the lysosome or vacuole resulting in the delivery of an inner vesicle (autophagic body) into the lumen of the degradative compartment. There are 16 proteins participating in autophagy pathway in human (http://ca.expasy.org/cgi-bin/get-entries? KW=Autophagy&view=tree). Abgent?s exclusive product line for autophagy research, 2-4 epitopes for each protein, provides antibodies against each protein in the pathway.
Bio References
Baehrecke EH. Nat Rev Mol Cell Biol. 6(6):505-10. (2005) Lum JJ, et al. Nat Rev Mol Cell Biol. 6(6):439-48. (2005) Greenberg JT. Dev Cell. 8(6):799-801. (2005) Levine B. Cell. 120(2):159-62. (2005) Shintani T and Klionsky DJ. Science. 306(5698):990-5. (2004)Tanida I., et al. Int. J. Biochem. Cell Biol. 36:2503-2518(2004)He H., et al. J. Biol. Chem. 278:29278-29287(2003) Tanida I., et al. J. Biol. Chem. 279:36268-36276(2004)
Gene ID
440738
Gene Name
MAP1LC3C
Subtitle
Synthetic peptide
Target/Specificity
The synthetic peptide sequence used to generate the antibody AP1804b was selected from the C-terminal region of human LC3 (APG8c). A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 500 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close